# Celadon Pharmaceuticals plc, “up to 80 million UK sales” says fund manager

- Link: https://www.directorstalkinterviews.com/celadon-pharmaceuticals-plc-%e2%80%9cup-to-80-million-uk-sales%e2%80%9d-says-fund-manager%c2%a0/4121112442
- Published: 2023-03-28T14:05:49+01:00
- Author: Jacob Brown

**[Miton UK MicroCap Trust plc](https://www.directorstalkinterviews.com/company/miton-uk-microcap-trust-plc/mini.l)(
[LON:MINI](https://www.directorstalkinterviews.com/company/miton-uk-microcap-trust-plc/mini.l))
Co-Fund Manager Gervais Williams **was asked by DirectorsTalk his views on portfolio
company **Celadon Pharmaceuticals plc** (LON:CEL) earlier this month.

DirectorsTalk asked, “In the health sector in January, Celadon Pharmaceuticals became
the first UK company to be registered to make cannabis-based medicines. They are
now waiting for the Home Office to update their license to begin supply, what are
your thoughts on the market opportunity there?

> **Gervais Williams commented:**
> It’s interesting, the UK currently imports quite a lot of cannabis oils and other
> products for medical use and actually, we don’t have any domestic production. 
> Celadon Pharmaceuticals are well positioned to take advantage of that and they’ve
> just been announced that the Home Office is likely to approve their application.
> That means they could possibly have up to 80 million of substitute sales from 
> the imports, which would drive substantial growth to the business up.
> The share price has actually risen from 55 through to about 130 recently. What
> that’s really says is, just like many other smaller quoted companies in the UK,
> their valuations are relatively low and on any good news, they cannot just improve
> but can see quite substantial improvements in the share price and this is a good
> example of that.
> On 14 March 2023, Celadon announced that its current Home Office licence has been
> successfully updated to allow the commercial sale of its high Δ9-tetrahydrocannabinol(“
> THC”) product, following the Company’s recent registration as a Good Manufacturing
> Practices (“GMP”) manufacturer by the UK Medicines and Healthcare products Regulatory
> Agency.

> **James Short, Chief Executive Officer of Celadon said:**
> “Following our milestone GMP certification, our updated Home Office licence now
> gives Celadon the opportunity to pursue revenue through the sale of our medicines,
> and to becoming a partner of choice in the pharmaceutical cannabis sector.
> It has been a great start to 2023 for Celadon and we continue to work hard to 
> get our products to market and, most importantly, to the patients that need our
> medicines most.”

Celadon Pharmaceuticals Plc is a UK-based pharmaceutical company specialising in
the research, cultivation, manufacturing and supply of cannabinoid-based medicines.

Share on: